Efficacy and Safety of Tocilizumab in COVID-19 Patients: Retrospective Study | ||||
| The Medical Journal of Cairo University | ||||
| Volume 90, Issue 12, December 2022, Page 2427-2434 PDF (269.73 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2022.295227 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| ALAA EID MOHAMED, M.D.; ASHRAF A. EL AGAMY, M.D.; AHMED W. EZZAT, M.D.; HASSAN ABD ELFATAH M. IBRAHIM, M.Sc. | ||||
| The Departments of Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University and Department of Intensive Care, Egypt Air Hospital | ||||
| Abstract | ||||
| Abstract Background: In December 2019, the severe acute respi-ratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of people across the globe and claimed hundreds of thousands of human lives. Indeed, elevated blood levels of IL-6 have been shown to correlate with COVID-19 disease severity and SARS-CoV-2 RNA blood levels in COVID-19 patients, and are also associated with a worse prognosis. Aim of Study: The aim of this work is to Study Efficacy and Safety of Tocilizumab in COVID-19 patients: The useful-ness of Tocilizumab (actemra) in patients with cytokine release storm and its efficacy to decrease mortality. Patients and Methods: This study was carried out in ICU Department, Egypt Air Hospitals, Retrospective clinical study from the period of 1/6/2020 to 1/6/2021, 100 patients with diagnosed Covid 19, (clinically, laboratory and radiologically). Results: Overall mortality in studied patients was 74 patients, 37 male and 37 female from the total 100 patients, Types of Organisms differentiation (cultured organisms) in studied patients, which 57% were candida, 21% were MRSA, 15% were Kliebsiella, 10%, Acinobacter and others were 4%. Incidence of improvement to hospital discharge studied pa-tients, From the total 100 patient 26 patients improved to home discharge differentiated moderate to severe. Conclusion: This study showed that tocilizumab did not reduce short-term mortality; low-certainty evidence from cohort studies suggests an association between tocilizumab and lower mortality. We observed a higher risk of infections and adverse events with tocilizumab use. | ||||
| Keywords | ||||
| Cyto kin e release storm; ICU; COVID 19; IL6; Tozilizumab | ||||
|
Statistics Article View: 87 PDF Download: 71 |
||||
